Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Inagaki

Showing results (281-290 of 310) with videos related to

Pageof 31
Sort By:
Neurology|November 27, 2002
Late infantile Hirschsprung disease-mental retardation syndrome with a 3-bp deletion in ZFHX1BM Yoneda, T Fujita, Y Yamada, et al.
Biochemical and Biophysical Research Communications|August 25, 2001
LL-Z1271alpha: an interleukin-1beta production inhibitorK Ichikawa, T Inagaki, H Kachi-Tonai, et al.
The Journal of Antibiotics|April 17, 1998
CJ-12,373, a novel topoisomerase II inhibitor: fermentation, isolation, structure elucidation and biological activitiesT Inagaki, K Kaneda, Y Suzuki, et al.
Acta Neuropathologica|February 24, 2001
Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brainsA Takeda, M Wakai, H Niwa, et al.
Current Cancer Drug Targets|April 21, 2012
anti-tumor effect of AlkB homolog 3 knockdown in hormone- independent prostate cancer cellsK Koike, Y Ueda, H Hase, et al.
The American Journal of Physiology|August 1, 1997
Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in ratsT Yamada, M Hoshino, T Hayakawa, et al.
The Journal of Antibiotics|February 6, 2002
A new antibiotic CJ-17,665 from Aspergillus ochraceusY Sugie, H Hirai, T Inagaki, et al.
The Journal of Antibiotics|April 17, 1998
New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activitiesK A Dekker, T Inagaki, T D Gootz, et al.
The Journal of Antibiotics|January 26, 1999
Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericium ramosumT Saito, F Aoki, H Hirai, et al.
Diabetes|December 16, 2000
Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytesJ C Parker, R K McPherson, K M Andrews, et al.
Pageof 31

Showing results (281-290 of 310) with videos related to

Sort By:
Pageof 31
Neurology|November 27, 2002
Late infantile Hirschsprung disease-mental retardation syndrome with a 3-bp deletion in ZFHX1BM Yoneda, T Fujita, Y Yamada, et al.
Biochemical and Biophysical Research Communications|August 25, 2001
LL-Z1271alpha: an interleukin-1beta production inhibitorK Ichikawa, T Inagaki, H Kachi-Tonai, et al.
The Journal of Antibiotics|April 17, 1998
CJ-12,373, a novel topoisomerase II inhibitor: fermentation, isolation, structure elucidation and biological activitiesT Inagaki, K Kaneda, Y Suzuki, et al.
Acta Neuropathologica|February 24, 2001
Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brainsA Takeda, M Wakai, H Niwa, et al.
Current Cancer Drug Targets|April 21, 2012
anti-tumor effect of AlkB homolog 3 knockdown in hormone- independent prostate cancer cellsK Koike, Y Ueda, H Hase, et al.
The American Journal of Physiology|August 1, 1997
Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in ratsT Yamada, M Hoshino, T Hayakawa, et al.
The Journal of Antibiotics|February 6, 2002
A new antibiotic CJ-17,665 from Aspergillus ochraceusY Sugie, H Hirai, T Inagaki, et al.
The Journal of Antibiotics|April 17, 1998
New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activitiesK A Dekker, T Inagaki, T D Gootz, et al.
The Journal of Antibiotics|January 26, 1999
Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericium ramosumT Saito, F Aoki, H Hirai, et al.
Diabetes|December 16, 2000
Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytesJ C Parker, R K McPherson, K M Andrews, et al.
Pageof 31